Optimised cell culture development for pharma, biotech, CMOs and media providers
Dr Anne Tolstrup | Head of Cell Culture II, Process Sciences, Biopharma Boehringer Ingelheim GmbH & Co. KG
Dr. Anne Tolstrup joined Boehringer-Ingelheim Biopharma in 2011 where she holds the position as Director for Cell Culture II in the Process Science department. Here, her group is dealing with all aspects of mammalian cell line development for manufacturing of therapeutic proteins, from vector construction over stable cell line generation to the upstream process. She obtained her PhD in Molecular and Cell Biology in 1994 from the University of Aarhus, Denmark. Following her studies she worked in the Danish biotech industry, early on as a hands-on Scientist and for the last 14 years in different Project Manager and Department Director positions. Her focus has always been on mammalian cell culture and expression technology. Latest, she spent 8 years at Symphogen A/S developing an expression technology for single-batch manufacturing of recombinant antibody mixtures. Dr Tolstrup holds the title of Adjunct Professor at the Danish Technical University, Systems Biology.
Share this
Appearances at this years' conference:
DAY 1 - Tuesday 28th February 2012
@ 15.20
Could automation be the answer to optimal cell line identification?
What are the limiting factors of existing early predictive tools?
Identification of rare, high-producing cell lines using automated platforms – could this allow better efficiency in identifying the right clones?
Considering the downstream processes from the beginning to improve overall process efficiency
› Dr Anne Tolstrup, Head of Cell Culture II, Process Sciences, Biopharma, Boehringer Ingelheim GmbH & Co. KG
@ 16.50
Panel discussion: evaluating the opportunities to develop cell culture bio-production
Given the need to produce biologics faster and cheaper, what strategies are the industry looking to in the future to achieve this?
Can understanding the benefits and limitations of different cell culture procedures aid in achieving the desired product in the shortest time with maximum yields?
Evaluating current technologies and methodologies which could deliver an optimized end-to-end production systems
› Dr Anne Tolstrup, Head of Cell Culture II, Process Sciences, Biopharma, Boehringer Ingelheim GmbH & Co. KG